On World Asthma Day 2024, AstraZeneca stands with the severe asthma community to highlight the condition’s profound impact on patients and healthcare systems. Severe asthma is a distinct form of asthma affecting 3-10% of cases, with up to 57% patients having uncontrolled disease. Hear from advocates Poppy and Tonya as they describe the challenges facing patients today.
To find out more about Respiratory and Immunology - Our therapy areas - AstraZeneca visit our website.
------------------------------------------------------------
Global site: www.astrazeneca.com/
Careers site: careers.astrazeneca.com/
Follow us:
Twitter: twitter.com/AstraZeneca
LinkedIn: www.linkedin.com/company/astrazeneca/
Instagram: www.instagram.com/astrazeneca/
Facebook: www.facebook.com/astrazenecacareers/
References:
1. Chung KF, Wenzel SE, Brozek JL, et al. 2014. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2): 343-73
2. Hekking PW, Wener RR, Amelink M, et al. 2015. The prevalence of severe refractory asthma. J Allergy Clin Immunol 135(4): 896-902
3. Wang E, et al. Characterization of Severe Asthma Worldwide. Chest. 2020;157(4):790-804.
astrazeneca